<DOC>
	<DOCNO>NCT02987114</DOCNO>
	<brief_summary>Open-label , clinical study evaluate safety , tolerability efficacy oral administration PTL101 ( cannabidiol ) treatment pediatric intractable epilepsy . Study include 4-week observation period ,12 week treatment 2 week follow .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Efficacy Oral Administration PTL101 ( Cannabidiol ) Adjunctive Treatment Pediatric Intractable Epilepsy</brief_title>
	<detailed_description>Open-label , single-center study , approximately 15 male female pediatric ( age 2-15 , inclusive ) patient , intractable epilepsy , stable dos antiepileptic drug ( AEDs ) , participate 4-week observation period.The patient begin 2-week dose-titration period . A maximum dose 25 mg/kg per day , 450 mg/day , low two . The subject participate maintenance dose 10 consecutive week , legal patient visit clinic first fifth week stable dose treatment period . During subsequent week tapering-off period follow phone contact . During study care giver fill seizure diary daily .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Drug Resistant Epilepsy</mesh_term>
	<criteria>1 . Pediatric subject refractory epilepsy 2 . 215 year old ( inclusive ) , male female 3 . History follow seizure type : tonic , clonic , tonicclonic form partial seizure , partial seizure secondarily generalize primary generalized , complex partial seizure drop attack ( tonic/atonic ) . 4 . At least four clinically countable seizure within 4 week study entry [ tonic , clonic , tonicclonic form partial seizure , partial seizure secondarily generalize primary generalized and/or complex partial seizure drop attack ( tonic/atonic ) ] 5 . Subject stable regimen 14 concomitant antiepileptic drug ( AEDs ) minimum 4 week prior enrollment 6 . History treatment least four AEDs , include one trial combination two concomitant drug , without successful seizure control 7 . Subjects vagal nerve stimulation system must stable setting minimum 6 month prior enrollment 8 . For subject undergoing dietary treatment ( e.g. , ketogenic modify Atkins diet ) : fat carbohydrate ratio must stable minimum eight week prior enrollment 9 . The subject 's legal guardian voluntarily provide consent participation study sign Informed Consent Form 10 . Completed seizure diary four week ( Â±3 day ) prior initiation dose titration period ( visit 2 ) . Subject consider screen failure seizures diary appropriately complete . 1 . The subject currently use use cannabisbased synthetic cannabinoid within three month study entry 2 . Subject unwilling abstain use cannabisbased synthetic cannabinoid throughout study period 3 . Neurodegenerative deteriorated neurological disease 4 . History heart failure 5 . Known family history ( firstdegree ) psychiatric disorder 6 . Psychosis past psychotic event and/or anxiety disorder 7 . Current history drug abuse/addiction 8 . Renal , hepatic ( ALT/AST &gt; 2x upper limit normal ( ULN ) , bilirubin &gt; 2x ULN ) , pancreatic dysfunction laboratory test abnormality , investigator 's discretion 9 . Clinically significant find baseline ECG 10 . Initiation felbamate treatment within 9 month screen 11 . Allergy CBD cannabinoid and/or formulation excipients 12 . Subject pregnant , lactating , planning pregnancy course study within 3 month study completion 13 . Subject legal guardian/caregiver unable comply study visits/requirements 14 . Subject currently enrol , yet complete period least 60 day since end another investigational device drug trial ( )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>